nPOC-POC Tenofovir
| Product Name | nPOC-POC Tenofovir |
|---|---|
| Alternate Names | Tenofovir Impurities, Impurities of Tenofovir |
| CAT No. | CS-O-10862 |
| CAS No. | 1217542-13-6 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 519.44 g/mol |
| Mol. For. | C₁₉H₃₀N₅O₁₀P |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Tenofovir |
| Purity | 99.39 |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | CCCOC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C |
| Canonical Smiles | CCCOC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C |
| InchIKey | FSHYLBFEGOTZGO-OAMPWVDCSA-N |
| Inchl | InChI=1S/C19H30N5O10P/c1-5-6-28-18(25)29-10-32-35(27,33-11-30-19(26)34-13(2)3)12-31-14(4)7-24-9-23-15-16(20)21-8-22-17(15)24/h8-9,13-14H,5-7,10-12H2,1-4H3,(H2,20,21,22)/t14-,35?/m1/s1 |
| IUPAC | [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propyl carbonate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
nPOC-POC Tenofovir is a novel prodrug of Tenofovir, which is an antiviral drug used for the treatment of HIV and hepatitis B. nPOC-POC Tenofovir is designed to improve the pharmacokinetics and bioavailability of the parent drug by increasing its solubility and stability in the body. The prodrug is rapidly converted to Tenofovir in the body, which then inhibits the reverse transcriptase enzyme of the virus, preventing the replication of the virus and slowing down the progression of the disease.
The chemical structure of nPOC-POC Tenofovir consists of two prodrug moieties, nPOC and POC, attached to the parent drug Tenofovir. These moieties improve the physicochemical properties of the drug by enhancing its water solubility and lipophilicity. The prodrug is metabolized by esterases in the body, releasing Tenofovir, which is then converted to its active form, Tenofovir diphosphate, inside the cells.
The usage of nPOC-POC Tenofovir is similar to that of Tenofovir, and it is administered orally as a tablet. The recommended dosage is 300 mg once daily for adults, and it is usually taken with food. The prodrug has been shown to be well-tolerated and safe in clinical trials, with no significant adverse effects reported. Its improved pharmacokinetic properties make it a promising candidate for the treatment of HIV and hepatitis B, especially in resource-limited settings where the availability of drugs with better bioavailability is limited.
Get an Instant Quote
Related Compounds
Tenofovir Monomethyl Ester | Tenofovir Impurity 89 | TAF Propyl ester Impurity | Tenofovir alafenamide monofumarate | Tenofovir Disoproxil Fumarate Impurity | Tenofovir Impurity 98 | Tenofovir Impurity 39 (RRR) 2,3-dihydroxysuccinate salt | Tenofovir Alafenamide Dimer Impurity II | nPOC-POC Tenofovir Fumarate | TenofovirDisoproxil Ethyl fumarate Impurity | Tenofovir Isopropyl Carbamate | Tenofovir EP Impurity C Succinate | Tenofovir disoproxil phosphate | Tenofovir isomer 6&1 | Ethyl Tenofovir Impurity | Diethylaminocarboxymethyl POC Tenofovir Fumarate | Tenofovir Alfenamide Amadori Rearrangement product | Tenofovir Alafenamide Dimer impurity | Tenofovir Impurity 36 (RSR) 2,3-dihydroxysuccinate salt | Tenofovir Disoproxil (S)-Isomer fumarate salt | Mono poc-isopropyl-Tenofovir fumarate salt | Tenofovir Impurity 62 | Mono-POC Tenofovir 6-Isopropyl Carbamate | Tenofovir disoproxil impurity L fumarate | Tenofovir DP-IV | Tenofovir Disoproxil T12 Impurity | Tenofovir Impurity 35 | Mono-POC Isopropyl Tenofovir | Desmethyl Tenofovir Disoproxil Fumarate | Tenofovir alafenamide Impurity 1 | TAF methyl ester | Tenofovir Impurity 59-D6 | Tenofovir impurity C fumarate salt | Diisopropyl Tenofovir Fumarate | Tenofovir Alafenamide Enantiomer | MOC-POC Tenofovir | Tenofovir diphosphate | Tenofovir alafenamide Impurity 2 | Tenofovir Related Compound 5 | Tenofovir Alafenamide Glycosamine product | Mono ester impurity (Tenofovir) | Tenofovir alafenamide Impurity 3 | Tenofovir Mono-POC methyl ester | Tenofovir disoproxil impurity L | Tri-POC Tenofovir Dimer | Diethylaminocarboxymethyl POC Tenofovir (Mixture of Diastereomers) | Desmethyl Tenofovir disoproxil | Tenofovir Alafenamide N-hydroxy methyl impurity | Tenofovir Disoproxil T5 Impurity | Tenofovir Disoproxil Dimer | Tenofovir Impurity 65 | Tenofovir alafenamide lactose Millard Reaction product-2 | Tenofovir DP-V | Tenofovir Diphenyl HemiFumarate salt | Mono-POC Ethyl Tenofovir | TAF SRS diastereomer | Tenofovir Mixed dimer | MOC-POC Tenofovir Fumarate | Tenofovir alafenamide impurity | Tenofovir Alafenamide fumarate | tenofovir related impurity | Tenofovir Bis ((R)-9-(2-Hydroxypropyl)adenine) dimer Acetate salt | Mono-POC Methyl Tenofovir Fumarate (Mixture of Diastereomers) | Tenofovir alafenamide Methyl ester impurity | Tenofovir Alafenamide Racemic D Isomer | Tenofovir alafenamide lactose Millard Reaction product-3 | Tenofovir alafenamide Impurity 5 | Tenofovir Alanine ester impurity | Tenofovir alafenamide (RRS) diasteroisomer | Tenofovir Disoproxil Isopropoxycarbonyl |